These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 26098992)
1. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening. Kay DM; Langfelder-Schwind E; DeCelie-Germana J; Sharp JK; Maloney B; Tavakoli NP; Saavedra-Matiz CA; Krein LM; Caggana M; Kier C; Pediatr Pulmonol; 2015 Aug; 50(8):771-80. PubMed ID: 26098992 [TBL] [Abstract][Full Text] [Related]
2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476 [TBL] [Abstract][Full Text] [Related]
3. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis. Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402 [TBL] [Abstract][Full Text] [Related]
5. Screening for cystic fibrosis in New York State: considerations for algorithm improvements. Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390 [TBL] [Abstract][Full Text] [Related]
6. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis. Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630 [TBL] [Abstract][Full Text] [Related]
7. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Ren CL; Desai H; Platt M; Dixon M Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969 [TBL] [Abstract][Full Text] [Related]
9. A survey of newborn screening for cystic fibrosis in Europe. Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C; J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. Parad RB; Comeau AM J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789 [TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years. Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays]. Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251 [TBL] [Abstract][Full Text] [Related]
13. Newborn Screening for Cystic Fibrosis in California. Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L; Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590 [TBL] [Abstract][Full Text] [Related]
14. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923 [TBL] [Abstract][Full Text] [Related]
15. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854 [TBL] [Abstract][Full Text] [Related]
16. CF versus CRMS: diagnostic challenges in cystic fibrosis. Temme R; Roggenbuck J; McNamara J Minn Med; 2012 Oct; 95(10):42-4. PubMed ID: 23193705 [TBL] [Abstract][Full Text] [Related]
17. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788 [TBL] [Abstract][Full Text] [Related]
19. Lessons learned from 20 years of newborn screening for cystic fibrosis. Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939 [TBL] [Abstract][Full Text] [Related]
20. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Padoan R; Bassotti A; Seia M; Corbetta C Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]